Key Highlights: Implications: The approval broadens AstraZeneca’s trastuzumab deruxtecan franchise in India from later-line metastatic use into the earlier, potentially larger HER2-positiv...
Key Highlights: Implications: This approval moves Enhertu + Perjeta into the front line of HER2‑positive metastatic breast cancer care in India, displacing taxane + tra...
